文献速递造血干细胞移植与细胞治疗血栓与止血

血清细胞角蛋白(CK)-18及CK18片段作为急性肝肠型GVHD生物标志物的前瞻性研究

A prospective study on serum Cytokeratin (CK)-18 and CK18 fragments as biomarkers of acute hepato-intestinal GVHD.
PubMed 文献 · Leukemia · 2018-06-27

这项前瞻性临床观察试验(NCT00935324)纳入109例移植患者,评估血清总CK18(tCK18)与凋亡型CK18片段(CK18F)预测即将发生的急性肝肠型GVHD及治疗反应的能力。36例(33%)在移植后中位56天怀疑发生I-IV级急性肝肠型GVHD,其中12例出现激素难治性GVHD。tCK18与CK18F在GVHD起病时均升高,tCK18在症状出现前7-14天即显著升高,起病时tCK18的AUC为0.927(p<0.001),CK18F为0.875(p<0.001)。

要点

  • tCK18与CK18F在急性肝肠型GVHD起病时均升高,可区分肠道组织学阴性的疑似患者。
  • 临床急性肝肠型GVHD患者中,tCK18在症状出现前7-14天已显著升高。
  • 起病时诊断已证实肝肠型急性GVHD的AUC:tCK18为0.927,CK18F为0.875(均p<0.001)。

核心结论

  • 本前瞻性研究验证了CK18F,并突出tCK18作为特异性生物标志物,适合用于改善对疑似即将发生及临床显现的急性肝肠型GVHD的预测与诊断。

研究设计与样本

  • 前瞻性临床观察试验(NCT00935324),在移植前及移植后每周间隔检测血清总CK18(tCK18)与凋亡型CK18F的动力学。
  • 共纳入109例患者。

主要发现

  • 36例(33%)在移植后中位56天怀疑发生I-IV级急性肝肠型GVHD,其中12例发生激素难治性GVHD。
  • tCK18与CK18F在GVHD起病时均升高,并可区分肠道组织学阴性的疑似急性肝肠型GVHD患者。
  • 在临床急性肝肠型GVHD患者中,tCK18在症状出现前7-14天已显著升高。
  • 起病时诊断已证实肝肠型急性GVHD的受试者工作特征曲线下面积:tCK18为0.927(p<0.001),凋亡型CK18F为0.875(p<0.001)。

关键数值与推荐

  • 起病时AUC:tCK18 0.927(p<0.001),凋亡型CK18F 0.875(p<0.001),对象为已证实肝肠型急性GVHD患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Apoptotic intestinal crypt cells are pathognomonic of acute intestinal graft versus host disease (GVHD). Serum levels of the apoptotic degradation product cytokeratin-18 fragments (CK18F) were associated with acute hepato-intestinal GVHD. Here we present a prospective clinical observational trial (NCT00935324) investigating serum levels of total CK18 (tCK18) and apoptotic CK18F to predict imminent acute hepato-intestinal GVHD and response to treatment. Total (t)CK18 and CK18F kinetics were measured before transplantation and in weekly intervals thereafter. In total 109 patients were enrolled. Acute hepato-intestinal GVHD grade I-IV was suspected in 36 patients (33%) at a median of 56 days post-transplant, 12 of these patients developed steroid-refractory GVHD. Both tCK18 and apoptotic CK18F increased at GVHD onset, and distinguished patients with suspected acute hepato-intestinal GVHD who were negative in intestinal histology. In patients with clinical acute hepato-intestinal GVHD, tCK18 significantly raised already 7-14 days before symptom onset. In receiver operator characteristics, areas under the curve at GVHD onset were 0.927 (p < 0.001) for tCK18 and 0.875 (p < 0.001) for apoptotic CK18F for patients with proven hepato-intestinal acute GVHD. This prospective study validates CK18F and highlights tCK18 as specific biomarkers suitable for improving prediction and diagnosis of suspected imminent and clinically manifest acute hepato-intestinal GVHD.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Sauer S, Hüsing J, Hajda J, et al. A prospective study on serum Cytokeratin (CK)-18 and CK18 fragments as biomarkers of acute hepato-intestinal GVHD. Leukemia. 2018. PMID: 29950693. doi:10.1038/s41375-018-0183-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。